Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Daratumumab
Related studies linked through entity extraction aliases.
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Status
- RECRUITING
- Phase
- PHASE3
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
- Status
- RECRUITING
- Phase
- PHASE2
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
- Status
- RECRUITING
- Phase
- PHASE2
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Status
- RECRUITING
- Phase
- PHASE3
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
- Status
- RECRUITING
- Phase
- PHASE2
Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study
- Status
- NOT_YET_RECRUITING
- Phase
- EARLY_PHASE1
The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2